ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) has unveiled promising early results from its Phase 1b trial of ORIC-944, a novel PRC2 inhibitor, in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer (mCRPC). The study reported broad and deep prostate-specific antigen (PSA) responses, with a 59% PSA50 response rate (47% confirmed, plus one pending) and a 24% confirmed PSA90 response rate.
These robust responses were seen across all dose levels and with both apalutamide and darolutamide combinations. Most patients remain on therapy, with several approaching one year or more of treatment.
A scientist examining cells in a lab, representing the company's dedication to developing specialty pharmaceuticals.
Safety data were also encouraging: the vast majority of adverse events were mild or moderate (Grade 1 or 2), primarily gastrointestinal, supporting long-term dosing suitability. Only one patient experienced a Grade 3 event, and there were no severe (Grade 4 or 5) treatment-related adverse events. ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) plans to advance two recommended Phase 2 doses for each combination into further study, with a global Phase 3 trial set to begin in the first half of 2026.
To support these efforts, ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced a $125 million private placement financing led by top healthcare investors, extending its cash runway into the second half of 2027 and through the anticipated Phase 3 trial readout.
While we acknowledge the potential of ORIC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORIC and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TechCrunch
34 minutes ago
- TechCrunch
Meta plans to automate many of its product risk assessments
In Brief An AI-powered system could soon take responsibility for evaluating the potential harms and privacy risks of up to 90% of updates made to Meta apps like Instagram and WhatsApp, according to internal documents reportedly viewed by NPR. NPR says a 2012 agreement between Facebook (now Meta) and the Federal Trade Commission requires the company to conduct privacy reviews of its products, evaluating the risks of any potential updates. Until now, those reviews have been largely conducted by human evaluators. Under the new system, Meta reportedly said product teams will be asked to fill out a questionaire about their work, then will usually receive an 'instant decision' with AI-identified risks, along with requirements that an update or feature must meet before it launches. This AI-centric approach would allow Meta to update its products more quickly, but one former executive told NPR it also creates 'higher risks,' as 'negative externalities of product changes are less likely to be prevented before they start causing problems in the world.' In a statement, Meta seemed to confirm that it's changing its review system, but it insisted that only 'low-risk decisions' will be automated, while 'human expertise' will still be used to examine 'novel and complex issues.'
Business Insider
an hour ago
- Business Insider
Morgan Stanley Sticks to Their Buy Rating for Akeso, Inc. (9926)
In a report released yesterday, Jack Lin from Morgan Stanley maintained a Buy rating on Akeso, Inc. (9926 – Research Report), with a price target of HK$87.00. The company's shares closed yesterday at HK$83.80. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Lin is ranked #6883 out of 9552 analysts. Currently, the analyst consensus on Akeso, Inc. is a Strong Buy with an average price target of HK$103.71, a 23.76% upside from current levels. In a report released yesterday, UBS also maintained a Buy rating on the stock with a HK$112.10 price target.
Business Insider
an hour ago
- Business Insider
UBS Sticks to Their Buy Rating for Akeso, Inc. (9926)
UBS analyst Chen Chen maintained a Buy rating on Akeso, Inc. (9926 – Research Report) yesterday and set a price target of HK$112.10. The company's shares closed yesterday at HK$83.80. Confident Investing Starts Here: Chen covers the Healthcare sector, focusing on stocks such as RemeGen Co. Ltd. Class H, Hangzhou Tigermed Consulting Co., Ltd. Class H, and Akeso, Inc.. According to TipRanks, Chen has an average return of 54.7% and a 78.57% success rate on recommended stocks. Currently, the analyst consensus on Akeso, Inc. is a Strong Buy with an average price target of HK$103.71, which is a 23.76% upside from current levels. In a report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a HK$87.00 price target.
